Euroapi S.A. announced that it has expanded its collaboration with Sanofi under the umbrella of their Master Agreement for Development and GMP Manufacturing Services, dated October 1, 2021, to support Sanofi's mRNA vaccine platform with the development of lipid nanoparticles. As part of this collaboration, EUROAPI will develop and optimize innovative chemical synthesis routes and manufacture GMP (Good Manufacturing Practices) batches for several second-generation cationic lipids through its Contract Development and Manufacturing Organization activity. As such, EUROAPI will focus on lipids that are currently being tested as part of Phase I/II clinical trials that will support Sanofi's mRNA vaccines platform, targeting indications including Flu.

Through its CDMO activity, leveraged by strong capabilities in its Budapest and Frankfurt development and manufacturing sites, EUROAPI is a global leader in lipid nanoparticles which are the key delivery enabler technologies for mRNA vaccines. Lipid nanoparticles play a crucial role in their ability to encapsulate, protect and transport mRNA to the cells where it will exert its therapeutic activity. EUROAPI will leverage its development and production capabilities in organic chemistry to provide Sanofi with clinical materials' supply.

With 330 scientists, EUROAPI benefits from unique expertise in complex chemistry, analytics and regulatory, enabling it to find the right synthesis pathway in a swift manner and meet health authorities' regulatory and quality requirements. The Company is also equipped with technology including large-scale chromatography purification equipment on its Budapest and Frankfurt sites that complies with the cGMPs (current Good Manufacturing Practices), allowing it to produce superior quality lipids. EUROAPI is a CDMO partner of choice for Sanofi thanks to the signing of the DSA.

EUROAPI is notably engaged in ten projects1 to develop and/or manufacture new molecular entities in the Sanofi's R&D portfolio. The CDMO activity is a strategic priority for EUROAPI and is expected to reach ~35% of its total net sales by the end of 2025. It has already obtained promising results since the establishment of a dedicated CDMO business development team in 2021, with 26 new projects won at the end of January 2022 spanning from 10 projects in pre-clinical/Phase 1, 6 projects in Phase 2, 4 projects in Phase 3 and 6 projects at commercial stage.